Lilly presents retatrutide Phase 3 data at ADA 2026 as obesity competition sharpens

Eli Lilly presented Phase 3 results for retatrutide, its investigational triple-agonist obesity drug, at the American Diabetes Association's 2026 Scientific Sessions in New Orleans, including the TRIUMPH-1 obesity trial and the TRANSCEND-T2D-1 diabetes study ^[2].

In TRIUMPH-1, which tested retatrutide in people with obesity but without diabetes, average weight loss reached 28.3% over 80 weeks ^[1][2]. Lilly announced the topline result on May 21 and compared the size of the effect to what bariatric surgery produces ^[2]. An earlier readout, TRIUMPH-4, reported in December, showed 26.6% placebo-adjusted weight loss at 68 weeks in people who have obesity or are overweight and also have knee osteoarthritis ^[2].

For comparison, the two drugs that lead the market today were less potent in their own trials. Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) produced about 21% weight loss at 72 weeks, and semaglutide (Ozempic, Wegovy, Rybelsus) about 15% at 68 weeks ^[1]. Retatrutide is not approved; Lilly has guided to a filing in the first quarter of 2027 ^[1].

The safety picture was part of the discussion. Lilly has reported a signal called dysesthesia — unpleasant or painful sensations — in more than a fifth of patients taking the 20-mg dose of retatrutide in TRIUMPH-4, and the signal also appeared in TRIUMPH-1, with rates rising as the dose rose ^[2]. Andy Hsieh, a healthcare research analyst at William Blair, told BioSpace that retatrutide belongs to a "different drug category" given its potency, and said the debate around it will center on the tradeoff between weight loss and tolerability ^[2].

Novo Nordisk brought its own next-generation candidate, CagriSema, a fixed-dose combination of semaglutide and the amylin analog cagrilintide ^[2]. In the head-to-head REDEFINE-4 study reported in February, people on CagriSema lost 23% of body weight on average at 84 weeks, while those on Zepbound lost 25.5%; the trial did not show non-inferiority ^[2]. Novo CEO Maziar Mike Doustdar said at the time of that readout that CagriSema would be "the first amylin-based product" and would "have the best weight loss label than any product marketed at that time" when it reaches the U.S. market early next year ^[2]. William Blair analysts said investors may be more interested in CagriSema's diabetes data — the Phase 3 REIMAGINE 1, 2 and 3 studies — than in its obesity data ^[2].

Behind the two leaders, Boehringer Ingelheim and Zealand Pharma presented detailed Phase 3 SYNCHRONIZE-1 data for survodutide, which showed a 16.6% weight reduction at 76 weeks versus 3.2% for placebo, with most of the loss coming from fat ^[2]. Roche's CT-388, a GLP-1/GIP dual agonist, previously showed 22.5% placebo-adjusted weight loss at 48 weeks ^[2]. IQVIA forecasts $92 billion in obesity medicine sales this year and up to $200 billion by 2027 and beyond, and obesity now accounts for 25% of overall pharma pipeline value ^[2].

One part of the competitive picture is not settled. A Medicare coverage change for GLP-1 medicines has been tied to the second half of 2026, but its eligibility rules, patient costs and start date have not been disclosed.

Why it matters for patients

The numbers set expectations, and they are worth reading carefully. A drug that produces roughly 28% weight loss ^[1][2] is well above what the currently approved options achieved in their trials ^[1]. But retatrutide is still investigational, with a filing guided to early 2027 ^[1] and no FDA decision announced, so nothing presented at the conference changes what a patient can be prescribed today.

Tolerability is the other half of the profile. Retatrutide's dysesthesia signal affected more than a fifth of patients on the 20-mg dose in one trial and rose with dose level ^[2]. Whether that pattern holds across the remaining Phase 3 studies has not been reported.

Coverage may matter as much as efficacy. If Medicare widens access to GLP-1 drugs, more beneficiaries could have the cost of treatment addressed, but the program's terms have not been disclosed, so who would qualify and what they would pay is not yet known.

What happens next

Lilly has said the remaining retatrutide Phase 3 readouts, TRIUMPH-2 and TRIUMPH-3, are due July 23, 2026, with a filing guided to the first quarter of 2027 ^[1]. An FDA decision on Novo Nordisk's CagriSema is expected in the second half of 2026 ^[1], and Novo expects a U.S. launch early next year ^[2].